

Cambridge University Press & Assessment
978-1-108-83866-5 — Alzheimer's Disease Drug Development
Edited by Jeffrey Cummings , Jefferson Kinney , Howard Fillit
Frontmatter
[More Information](#)

Alzheimer's Disease Drug Development

Alzheimer's Disease Drug Development

Research and Development Ecosystem

Edited by
Jeffrey Cummings
University of Nevada, Las Vegas
Jefferson Kinney
University of Nevada, Las Vegas
Howard Fillit
Alzheimer's Drug Discovery Foundation



Cambridge University Press & Assessment
978-1-108-83866-5 — Alzheimer's Disease Drug Development
Edited by Jeffrey Cummings , Jefferson Kinney , Howard Fillit
Frontmatter
[More Information](#)

CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

One Liberty Plaza, 20th Floor, New York, NY 10006, USA

477 Williamstown Road, Port Melbourne, VIC 3207, Australia

314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India

103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781108838665

DOI: 10.1017/9781108975759

© Cambridge University Press 2022

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2022

Printed in the United Kingdom by TJ Books Limited, Padstow Cornwall

A catalogue record for this publication is available from the British Library.

ISBN 978-1-108-83866-5 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

The editors dedicate this book to all those doing the hard work of developing new therapies for Alzheimer’s disease and to all those who will join the battle and contribute to the emergence of new therapies to improve the lives of those with Alzheimer’s disease and those at risk for this mind-robbing disease.

Jeffrey Cummings dedicates this book to Kate Zhong, life partner, best friend, and incomparable traveling companion on life’s journey.

Jefferson Kinney dedicates this book to his wife Debi Kinney and son Parker Kinney for all the inspiration they have provided.

Howard Fillit dedicates this book to his wife and best friend, Susan Kind, for her many years of support and love. He also thanks Leonard and Ronald Lauder and all his colleagues at the Alzheimer’s Drug Discovery Foundation for their partnership and their efforts in conquering Alzheimer’s disease.

Contents

List of Contributors xi
Foreword xix
Acknowledgments xx

Section 1: Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem

1 **Alzheimer’s Disease Drug Development: A Research and Development Ecosystem** 1
Jeffrey Cummings, Jefferson Kinney, and Howard Fillit

2 **Drug Development for Alzheimer’s Disease: An Historical Perspective** 25
Howard Fillit and Jeffrey Cummings

3 **Alzheimer’s Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing** 34
Kurt R. Brunden, Goodwell Nzou, and Carlo Ballatore

4 **The Harrington Discovery Institute and Alzheimer’s Disease Drug Development** 45
Andrew A. Pieper, J. Simon Mazza-Lunn, and Diana R. Wetmore

5 **Repurposed Agents in Alzheimer’s Disease Drug Development** 54
Clive Ballard and Janet Sultana

6 **Artificial Intelligence in Alzheimer’s Drug Discovery** 62
Feixiong Cheng and Jeffrey Cummings

Section 2: Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs

7 **Role of Animal Models in Alzheimer’s Disease Drug Development** 73

Jefferson Kinney, Amanda M. Leisgang Osse, Bruce Lamb, Adrian Oblack, Alan D. Palkowitz, and Frank J. Belas, Jr.

8 **Use of Induced Pluripotent Stem Cell-Derived Neuronal Disease Models from Patients with Familial Early-Onset Alzheimer’s Disease in Drug Discovery** 95
Brenda Hug, Rudolph E. Tanzi, and Steven L. Wagner

9 **Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer’s Disease Drug Discovery** 106
Min Su Kang, Eduardo R. Zimmer, Julie Ottoy, Monica Shin, Marcel Seungsu Woo, Arturo Aliaga, Gassan Massarweh, A. Claudio Cuello, Serge Gauthier, and Pedro Rosa-Neto

10 **Biobanking and Biomarkers in the Alzheimer’s Disease Drug-Development Ecosystem** 123
Jefferson Kinney and Arnold Salazar

Section 3: Alzheimer’s Disease Clinical Trials

11 **Phase 1 Trials in Alzheimer’s Disease Drug Development** 135
Manfred Windisch

12 **The Importance of Phase 2 in Drug Development for Alzheimer’s Disease** 150
Philip Scheltens, Willem de Haan, Roos J. Jutten, Everhard Vijverberg, Arno de Wilde, and Niels Prins

Contents

13	Alzheimer's Disease Drug Development in Pharmaceutical Companies 162	21	The Role of Online Registries in Accelerating Alzheimer's Disease Drug Development 257
	Eric Siemers, Robert A. Dean, James E. Senetar, Janice M. Hitchcock, and Russell L. Barton		Sarah Walter, Jessica Langbaum, and Rachel Nosheny
14	Trial Site Infrastructure and Management: Importance to Alzheimer's Disease Drug Development 170	22	Data Safety Monitoring Boards in Alzheimer's Disease Trials 266
	Marwan Sabbagh, Jiong Shi, Philip Scheltens, and Niels Prins		Emily D. Clark and Anton P. Porsteinsson
15	ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development 177	23	Globalization of Alzheimer's Disease Clinical Trials 275
	Paul S. Aisen, Rema Raman, Michael S. Rafii, Reisa A. Sperling, and Ronald C. Petersen		Huali Wang, Tao Wang, Shifu Xiao, and Xin Yu
16	The European Prevention of Alzheimer's Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia 190	24	The Use and Development of Clinical Measures of Alzheimer's Disease Trials 281
	Craig W. Ritchie, on behalf of the EPAD Consortium		John Harrison
17	The Global Alzheimer's Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials 207	25	Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer's Disease Clinical Trials 292
	Jason Bork, Cyndy Cordell, John Dwyer, Gabe Goldfeder, Debra R. Lappin, Richard Mohs, Julie Neild, Rona Schillinger, Jill Smith, Katy Smith, Leigh Zisko, and George Vradenburg		Rhoda Au, Honghuang Lin, and Vijaya B. Kolachalama
18	Clinical Trial Development in Frontotemporal Lobar Degeneration 216	26	Expanded Access and Compassionate Use in Alzheimer's Disease Drug Development 301
	Peter A. Ljubenkov and Adam Boxer		Diana Kerwin
19	Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials 232	27	The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program 309
	Suzanne B. Hendrix, Jessie Nicodemus-Johnson, Logan Kowallis, Newman Knowlton, Sean Hennessey, Samuel P. Dickson		John J. Sramek, Henry Riordan, Michael F. Murphy, and Neal R. Cutler
20	Alzheimer's Disease Trial Recruitment and Diversifying Trial Populations 249	28	The Role of Regulatory Agencies in Alzheimer's Disease Drug Development 319
	Samantha E. John		Cristina Sampaio and Swati Sathe
		29	Alzheimer's Disease Clinical Trial Study Partners 333
			Joshua Grill
		30	From Trials to Practice: Are We Ready for a Disease-Modifying Treatment? 343
			Soeren Mattke

31 **Best Practices for Clinical Trials during COVID-19** 354
Saif-Ur-Rahman Paracha, William Maurice Redden, and George Grossberg

Section 4: Imaging and Biomarker Development in Alzheimer's Disease Drug Discovery

32 **Development of Fluid Biomarkers for Alzheimer's Disease** 361
Kaj Blennow

33 **Brain Imaging for Alzheimer's Disease Clinical Trials** 375
Dawn C. Matthews and Mark E. Schmidt

34 **Sharing of Alzheimer's Disease Research Data in the Global Alzheimer's Association Interactive Network** 395
Cally Xiao, Scott C. Neu, and Arthur W. Toga

35 **Pharmacogenetics in Alzheimer's Disease Drug Discovery and Personalized Treatment** 404
Ramon Cacabelos

36 **The Role of Electroencephalography in Alzheimer's Disease Drug Development** 418
Willem de Haan and Niels Prins

Section 5: Academic Drug-Development Programs

37 **Institutional Review Boards and Oversight of Alzheimer's Disease Trials** 429
Emily A. Largent and Joshua Grill

38 **SPARKing Drug Development for Alzheimer's Disease in Academia** 437
Daria Mochly-Rosen and Kevin V. Grimes

39 **The Role of Professional Associations and Patient Advocacy in Advancing**

Alzheimer's Disease Drug Development 449
Amir Kalali and Gil Bashe

Section 6: Public–Private Partnerships in Alzheimer's Disease Drug Development

40 **Alzheimer's Disease Neuroimaging Initiative** 455
Charles Bernick

Section 7: Funding and Financing Alzheimer's Disease Drug Development

41 **Financing Alzheimer's Disease Drug Development** 465
Jayna Cummings, Amanda Hu, Angela Su, and Andrew W. Lo

42 **Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development** 480
Lauren G. Friedman, Meriel Owen, Alessio Travaglia, and Howard Fillit

43 **Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development** 486
Maria C. Carrillo, Emily A. S. Meyers, and Heather M. Snyder

44 **The Role of Philanthropy in Alzheimer's Disease Therapeutic Development** 496
Cara Altimus

45 **National Institute on Aging's Alzheimer's Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer's Disease and Related Dementias** 503
Laurie Ryan, Suzana Petanceska, and Lorenzo Refolo

Cambridge University Press & Assessment
978-1-108-83866-5 — Alzheimer's Disease Drug Development
Edited by Jeffrey Cummings , Jefferson Kinney , Howard Fillit
Frontmatter
[More Information](#)

Contents

46	Alzheimer’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study	513	48	Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development	533
	Susan Catalano			Pragati Katiyar, Armineh L. Ghazarian, Zane Martin, and Todd Haim	
47	Introduction to Venture Capital in Alzheimer’s Disease Drug Development	524			
	Laurence Barker, Jonathan Behr, and Christian Jung				

Index 544

Contributors

Paul S. Aisen, MD
University of Southern California Alzheimer’s
Therapeutic Research Institute
San Diego, CA, USA

Arturo Aliaga
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
Douglas Mental Health Research Institute
McConnell Brain Imaging Centre
McGill University
Quebec, Canada

Cara Altimus, PhD
Center for Strategic Philanthropy
Milken Institute
Washington, DC, USA

Rhoda Au, PhD
Department of Anatomy and Neurobiology
Boston University School of Medicine
Boston, MA, USA

Clive Ballard, MD, MRC Psych
College of Medicine and Health
University of Exeter
Exeter, United Kingdom

Carlo Ballatore, PhD
Skaggs School of Pharmacy and Pharmaceutical
Sciences
University of California San Diego
La Jolla, CA, USA

Laurence Barker, PhD, MBA
Dementia Discovery Fund at SV Health
Investors
London, United Kingdom

Russell L. Barton, MS
PharmaSagacity Consulting, LLC
Carmel, IN, USA

Gil Bashe
Finn Partners
New York, NY, USA

Jonathan Behr, PhD
Dementia Discovery Fund at SV Health Investors
London, United Kingdom

Frank J. Belas, Jr., PhD
IUSM–Perdue TREAT-AD Center
Indiana University School of Medicine
Biotechnology Research and Training Center
Indianapolis, IN, USA

Charles Bernick, MD, MPH
Memory and Brain Wellness Center
University of Washington School of Medicine
Seattle, WA, USA

Kaj Blennow, MD, PhD
Clinical Neurochemistry Laboratory
Institute of Neuroscience and Physiology
The Sahlgrenska Academy at University of
Gothenburg, Molndal Campus
Sahlgrenska University Hospital
Molndal, Sweden

Jason Bork, BS
Global Alzheimer’s Platform
Washington, DC, USA

Adam Boxer, MD, PhD
Weill Institute for Neurosciences
Memory and Aging Center
University of California San Francisco
San Francisco, CA, USA

Kurt R. Brunden, PhD
Center for Neurodegenerative Disease Research
University of Pennsylvania, Perelman School of
Medicine
Philadelphia, PA, USA

List of Contributors

Ramon Cacabelos, MD, PhD
EuroEspes Biomedical Research Center
International Center of Neuroscience and
Genomic Medicine
Bergondo, Corunna, Spain

Maria C. Carrillo, PhD
Alzheimer's Association
Chicago, IL, USA

Susan Catalano, PhD
Cognition Therapeutics
Pittsburgh, PA, USA

Feixiong Cheng, PhD
Genomic Medicine Institute, Lerner Research
Institute
Cleveland Clinic
Cleveland, OH, USA

Emily D. Clark, DO
Alzheimer's Disease Care, Research Education
Program (AD-CARE)
University of Rochester School of Medicine and
Dentistry
Rochester, NY, USA

Cyndy Cordell, MBA
Global Alzheimer's Platform
Washington, DC, USA

A. Claudio Cuello, MD
Department of Pharmacology and Therapeutics
McGill University
Quebec, Canada

Jayna Cummings, MBA
Laboratory for Financial Engineering
Sloan School of Management
Massachusetts Institute of Technology
Cambridge, MA, USA

Jeffrey Cummings, MD, ScD
Chambers–Grundy Center for Transformative
Neuroscience
Department of Brain Health
School of Integrated Health Sciences
University of Nevada Las Vegas
Las Vegas, NV, USA

Neal R. Cutler, MD
Worldwide Clinical Trials
Beverly Hills, CA/Wayne, PA, USA

Robert A. Dean, PhD, MD
Robert A. Dean Consulting, LLC
Whitestown, IN, USA

Samuel P. Dickson, PhD
Pentara Corporation
Millcreek, UT, USA

John Dwyer, JD
Global Alzheimer's Platform
Washington, DC, USA

Howard Fillit, MD
Alzheimer's Drug Discovery Foundation
New York, NY, USA

Lauren G. Friedman, PhD
Alzheimer's Drug Discovery Foundation
New York, NY, USA

Serge Gauthier, MD, FRCPC
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
Douglas Mental Health Research Institute
McGill University
Quebec, Canada

Armineh L. Ghazarian, MSF
National Institute on Aging
Bethesda, MD, USA

Gabe Goldfeder, MA
Global Alzheimer's Platform
Washington, DC, USA

Joshua Grill, PhD
Institute for Memory Impairments and
Neurological Disorders
Department of Psychiatry and Human Behavior;
Department of Neurobiology
Alzheimer's Disease Research Center
University of California Irvine
Irvine, CA, USA

Kevin V. Grimes, MD
Department of Chemical and Systems Biology
Stanford University School of Medicine
Stanford, CA, USA

George Grossberg, MD
Department of Psychiatry and Behavioral
Neuroscience
Saint Louis University School of Medicine
St. Louis, MO, USA

List of Contributors

Willem de Haan, MD, PhD
Department of Neurology and Alzheimer Center;
Department of Clinical Neurophysiology
Amsterdam University Medical Center
Amsterdam, The Netherlands

Todd Haim, PhD
National Institute on Aging
Bethesda, MD, USA

John Harrison, PhD
Metis Cognition, Ltd
Wiltshire, UK

Suzanne Hendrix, PhD
Pentara Corporation
Millcreek, UT, USA

Sean P. Hennessey, MS
Pentara Corporation
Millcreek, UT, USA

Janice M. Hitchcock, PhD
Hitchcock Regulatory Consulting, Inc.
Fishers, IN, USA

Amanda Hu
Laboratory for Financial Engineering
Sloan School of Management
Massachusetts Institute of Technology (MIT)
Cambridge, MA, USA

Brenda Hug, BS
Veterans Administrative San Diego Healthcare
System
La Jolla, CA, USA

Samantha E. John, PhD
Department of Brain Health
School of Integrated Health Sciences
University of Nevada Las Vegas
Las Vegas, NV, USA

Christian Jung, PhD
Dementia Discovery Fund at SV Health
Investors
London, United Kingdom

Roos J. Jutten, PhD
Department of Neurology and Alzheimer Center
Amsterdam University Medical Center
Amsterdam, The Netherlands
and
Department of Neurology

Massachusetts General Hospital, Harvard Medical
School
Boston, MA, USA

Amir Kalali, MD
The Decentralized Trials and Research Alliance;
CNS Summit; The International Society for CNS
Drug Development; The International Society for
CNS Clinical Trials and Methodology
San Diego, CA, USA

Min Su Kang, PhD
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
Douglas Mental Health Research Institute
McConnell Brain Imaging Centre
McGill University
Quebec, Canada

Pragati Katiyar, PhD
National Institute on Aging
Bethesda, MD, USA

Diana Kerwin, MD
Kerwin Medical Center
Dallas, TX, USA

Jefferson Kinney, PhD
Department of Brain Health
School of Integrated Health Sciences
University of Nevada Las Vegas
Las Vegas, NV, USA

Dr Logan Kowallis, PhD
AltaSciences, Laval, QC, Canada

Newman T. Knowlton, MS
Pentara Corporation
Millcreek, UT, USA

Vijaya B. Kolachalama, PhD
Section of Computational Biomedicine
Department of Medicine
Boston University School of Medicine
Boston, MA, USA

Bruce Lamb, PhD
Stark Neuroscience Research Institute
Indiana University School of Medicine
Indianapolis, IN, USA

Jessica Langbaum, PhD
Banner Alzheimer's Institute
Phoenix, AZ, USA

List of Contributors

Debra R. Lappin, JD

Faegre Drinker Consulting
Washington, DC, USA

Emily A. Largent, JD, PhD, RN

Department of Medical Ethics and Health Policy
University of Pennsylvania, Perelman School of
Medicine
Philadelphia, PA, USA

Amanda M. Leisgang Osse

Department of Brain Health
School of Integrated Health Sciences
University of Nevada Las Vegas
Las Vegas, NV, USA

Honghuang Lin, PhD

Section of Computational Biomedicine,
Department of Medicine
Boston University School of Medicine
Boston, MA, USA

Peter A. Ljubenkov, MD

Weill Institute for Neurosciences, Memory and
Aging Center
University of California San Francisco
San Francisco, CA, USA

Andrew W. Lo, PhD

Laboratory for Financial Engineering,
Sloan School of Management
Computer Science and Artificial Intelligence
Laboratory
Massachusetts Institute of Technology
Cambridge, MA, USA

Zane Martin, PhD

National Institute on Aging
Bethesda, MD, USA

Gassan Massarweh, PhD

McConnell Brain Imaging Centre
McGill University
Quebec, Canada

Dawn C. Matthews, MS, MBA

ADM Diagnostics, Inc.
Northbrook, IL, USA

Soeren Mattke, MD, DSc

The USC Brain Health Observatory
University of Southern California
Los Angeles, CA, USA

J. Simon Mazza-Lunn, PhD

Harrington Discovery Institute
University Hospitals Health System
Cleveland, OH, USA

Emily A. S. Meyers, PhD

Alzheimer's Association
Chicago, IL, USA

Daria Mochly-Rosen, PhD

Department of Chemical and Systems
Biology
Stanford University School of Medicine
Stanford, CA, USA

Richard Mohs, PhD

Global Alzheimer's Platform
Washington, DC, USA

Michael F. Murphy, MD, PhD

Worldwide Clinical Trials
Beverly Hills, CA/Wayne, PA, USA

Julie Neild, MTSC

Global Alzheimer's Platform
Washington, DC, USA

Scott C. Neu, PhD

Laboratory of Neuro Imaging
USC Stevens Neuroimaging and Informatics
Institute
Keck School of Medicine
University of Southern California
Los Angeles, CA, USA

Jessie Nicodemus-Johnson, PhD

Pentara Corporation
Millcreek, UT, USA

Rachel Nosheny, PhD

Department of Psychiatry
University of California San Francisco/San
Francisco Veteran's Administration Medical
Center
San Francisco, CA, USA

Goodwell Nzou, PhD

Center for Neurodegenerative Disease Research
University of Pennsylvania, Perelman School of
Medicine
Philadelphia, PA, USA

Adrian Oblack, PhD

Stark Neuroscience Research Institute

List of Contributors

Indiana University School of Medicine
Indianapolis, IN, USA

Julie Ottoy, PhD
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
McGill University
Quebec, Canada

Meriel Owen, PhD
Alzheimer's Drug Discovery Foundation
New York, NY, USA

Alan D. Palkowitz, PhD
IUSM–Perdue TREAT-AD Center
Indiana University School of Medicine
Indiana Biosciences Research Institute
Indianapolis, IN, USA

Saif-Ur-Rahman Paracha, MD
Department of Psychiatry and Behavioral
Neuroscience
Saint Louis University School of Medicine
St. Louis, MO, USA

Suzana Petanceska, PhD
National Institute on Aging
Bethesda, MD, USA

Ronald C. Petersen, MD, PhD
Mayo Clinic
Rochester, MN, USA

Andrew A. Pieper, MD, PhD
Harrington Discovery Institute
University Hospitals Health System
Cleveland, OH, USA
and
Department of Psychiatry, Case Western Reserve
University
Louis Stokes VA Medical Center of Cleveland
Cleveland, OH, USA

Anton P. Porsteinsson, MD
Alzheimer's Disease Care, Research, and
Education Program (AD-CARE)
University of Rochester School of Medicine and
Dentistry
Rochester, NY, USA

Niels Prins, MD, PhD
Alzheimer Center

Amsterdam University Medical Center
Amsterdam, The Netherlands

Michael S. Rafii, MD, PhD
USC Alzheimer's Therapeutic Research Institute
San Diego, CA, USA

Rema Raman, PhD
USC Alzheimer's Therapeutic Research Institute
San Diego, CA, USA

William Maurice Redden, MD
Department of Psychiatry and Behavioral
Neuroscience
Saint Louis University School of Medicine
St. Louis, MO, USA

Lorenzo Refolo, PhD
National Institute on Aging
Bethesda, MD, USA

Henry Riordan, PhD
Worldwide Clinical Trials
Beverly Hills, CA/Wayne, PA, USA

Craig W. Ritchie, MD, PhD
Centre for Dementia Prevention
The University of Edinburgh
Edinburgh, United Kingdom

Pedro Rosa-Neto, MD, PhD
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
Douglas Mental Health Research Institute
McConnell Brain Imaging Centre
McGill University
Quebec, Canada

Laurie Ryan, PhD
National Institute on Aging
Bethesda, MD, USA

Marwan Sabbagh, MD
Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
Phoenix, AZ, USA

Arnold Salazar, PhD
Department of Brain Health
School of Integrated Health Sciences
University of Nevada Las Vegas
Las Vegas, NV, USA

List of Contributors

Cristina Sampaio, MD, PhD
CHDI Management/CHDI Foundation, Inc.
Princeton, NJ, USA
and
Laboratory of Clinical Pharmacology
Lisbon School of Medicine
University of Lisbon
Lisbon, Portugal

Swati Sathe, MD
CHDI Management/CHDI Foundation, Inc.
Princeton, NJ, USA
and
Rutgers University
Newark, NJ, USA

Philip Scheltens, MD, PhD
Alzheimer Center
Amsterdam University Medical Center; Life
Science Partners
Amsterdam, The Netherlands

Rona Schillinger, BS
Global Alzheimer's Platform
Washington, DC, USA

Mark E. Schmidt, MD
Neuroscience Therapeutic Area
Janssen Research and Development
Division of Janssen Pharmaceutica, NV
Beerse, Belgium

James E. Senetar, PharmD
JES Consulting, LLC
Zionsville, IN, USA

Jiong Shi, MD, PhD
Cleveland Clinic Lou Ruvo Center for Brain
Health
Las Vegas, NV, USA

Monica Shin, MS
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
McGill University
Quebec, Canada

Eric Siemers, MD
Siemers Integration, LLC
Zionsville, IN, USA

Jill Smith, MA
Global Alzheimer's Platform
Washington, DC, USA

Katy Smith, MA
Global Alzheimer's Platform
Washington, DC, USA

Heather M. Snyder, PhD
Alzheimer's Association
Chicago, IL, USA

Reisa A. Sperling, MD
Harvard Medical School
Boston, MA, USA

John J. Sramek, Pharm D
Worldwide Clinical Trials
Beverly Hills, CA/Wayne, PA, USA

Angela Su
Laboratory for Financial Engineering
Sloan School of Management
Massachusetts Institute of Technology
Cambridge, MA, USA

Janet Sultana, B Pharm, MSc, PhD
College of Medicine and Health, University of
Exeter
Exeter, United Kingdom

Rudolph E. Tanzi, PhD
Genetics and Aging Research Unit
Department of Neurology
Massachusetts General Hospital
Boston, MA, USA

Arthur W. Toga, PhD
Laboratory of Neuro Imaging
USC Stevens Neuroimaging and Informatics
Institute
Keck School of Medicine
University of Southern California
Los Angeles, CA, USA

Alessio Travaglia, PhD
Alzheimer's Drug Discovery Foundation
New York, NY, USA

Everhard Vijverberg, MD, PhD
Department of Neurology and Alzheimer Center

List of Contributors

Amsterdam University Medical Center; Brain
Research Center
Amsterdam, The Netherlands

George Vradenburg, JD
Global Alzheimer's Platform
USAgainstAlzheimer's
Washington, DC, USA

Steven L. Wagner, PhD
Department of Neurosciences
School of Medicine
University of California San Diego
San Diego, CA, USA

Sarah Walter, MSc
Alzheimer's Therapeutic Research Institute
University of Southern California
San Diego, CA, USA

Huali Wang, MD, PhD
Dementia Care and Research Center
Clinical Research Division
Peking University Institute of Mental Health
Beijing, China

Tao Wang, MD, PhD
Department of Geriatric Psychiatry
Shanghai Mental Health Center
Shanghai Jiao Tong University School of Medicine
Shanghai, China

Diana R. Wetmore, PhD
Harrington Discovery Institute
University Hospitals Health System
Cleveland, OH, USA

Arno de Wilde, MD, PhD
Department of Neurology and Alzheimer Center
Amsterdam University Medical Center; Life
Science Partners
Amsterdam, The Netherlands

Manfred Windisch, PhD
NeuroScios GmbH
St. Radegund/Graz
Austria

Marcel Seungsu Woo, MD
Translational Neuroimaging Laboratory
Research Centre for Studying in Aging
McGill University
Quebec, Canada

Cally Xiao, PhD
Laboratory of Neuro Imaging
USC Stevens Neuroimaging and Informatics
Institute
Keck School of Medicine
University of Southern California
Los Angeles, CA, USA

Shifu Xiao, MD, PhD
Department of Geriatric Psychiatry
Shanghai Mental Health Center
Shanghai Jiao Tong University School
of Medicine
Shanghai, China

Xin Yu, MD
Beijing Municipal Key Laboratory of
Translational Research on Diagnosis and
Treatment of Dementia
Dementia Care and Research Center
Peking University Institute of Mental Health
Beijing, China

Eduardo R. Zimmer, PhD
Department of Pharmacology
Univerisdade Federal do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil

Leigh Zisko, MPH
Global Alzheimer's Platform
Washington, DC, USA

Foreword

Alzheimer's Disease Drug Development: A Research and Development Ecosystem captures the complexity of Alzheimer's disease (AD) drug development and provides a comprehensive set of perspectives from the many stakeholders involved in discovering and developing new therapies for AD.

There is no greater unmet therapeutic need for humanity than effective therapies for brain disorders. The suffering caused by these conditions and other neurodegenerative disorders is overwhelming and is burdened with substantial stigma. Therefore, I have devoted my professional life to changing the way brain disorders such as schizophrenia, depression, AD, among others are not only treated, but also viewed by society. From my time with the National Institutes of Health, Janssen and Johnson & Johnson, where I serve as the Global Head of Science for Minds, my colleagues and I recognize there is still much to uncover about brain disorders due to the rich complexity of the brain and the challenges in accessing it. But that is not a reason to stop – especially as we enter the golden age of neuroscience, driven largely by scientific breakthroughs and accelerated regulatory pathways.

Through our continued commitment in neuroscience, we have uncovered new tools which promise to help us succeed in brain disorder and AD drug development. Fluid biomarkers from blood and spinal fluid, as well as imaging biomarkers, are increasingly allowing us to identify proper populations for inclusion in clinical trials and to more comprehensively understand the effects of our drugs on the biology of complex brain disorders. These advances are described in detail in *Alzheimer's Disease Drug Development: A Research and Development Ecosystem*.

I believe that therapeutic efforts coupled with education will have a marked effect on the lives of those living with brain disorders and their caregivers, but also recognize the importance and value of collaborations and perspectives from key stakeholders in the industry. *Alzheimer's Disease Drug Development: A Research and Development Ecosystem* provides a roadmap for creating this collaborative foundation that will ultimately lead to success for our enterprise and the patient population.

Husseini Manji, MD, FRCPC
Global Head, Science for Minds, Johnson & Johnson

Acknowledgments

The editors gratefully acknowledge the tremendous effort, organizational expertise, and enthusiasm of Mary Kay Tarkanian brought to bear throughout the process of developing this volume.

Dr. Cummings and Dr. Kinney acknowledge the tremendous support of Joy Chambers-Grundy

whose generosity has accelerated the study of drug development and expanded the ecosystem required to advance urgently needed new therapies for patients with brain disorders.